[ad_1]
The human papillomavirus (HPV) vaccine is given to prevent a sexually transmitted infection that can cause cancer. In 2009, the UK's National Health Service began offering the vaccine to 12- and 13-year-old girls in schools across the country.
(Photo by Joe Raedle / Getty Images)
Researchers at the University of Edinburgh concluded that a national HPV vaccination program offered to girls had resulted in a "dramatic reduction" in the risk of developing cervical cancer later in the world. life.
The UK's National Health Service (NHS) launched a program in 2009 to provide 12- and 13-year-old girls with the human papillomavirus (HPV) vaccine, a group of sexually transmitted viruses that can cause cancer of the cervix. 39; uterus.
Scientists from Strathclyde, Edinburgh, Aberdeen and Glasgow Caledonian Universities have teamed up to analyze cervical cancer screening and vaccination records of 138,692 women who had first screened for cervical cancer at the time of their first cervix screening. age of 20 between 2008 and 2016.
A HISTORY OF CERVICAL CANCER BY A FEMININE ACTION TO GIVE AVENANCE TO OTHERS WHERE THEY SAID THAT THEY ARE TOO YOUNG FOR A FREE PAPER
"Routine vaccination of the bivalent HPV vaccine in 12- to 13-year-old girls in Scotland has led to a dramatic reduction in the number of pre-invasive cervical diseases," says the study published in the British Medical Journal. "The bivalent vaccine is confirmed as being a very effective vaccine and should dramatically reduce the incidence of cervical cancer."
Cervical cancer is the second most common type of cancer among women under 35 in the UK, the NHS reported. Although there are more than 100 types of HPV, some strains of the virus are considered high risk because of their connection to cervical cancer.
The researchers evaluated the level of abnormal cells, called cervical intraepithelial neoplasia (CIN), detected during the first screening of each woman. The NHS classifies CIN in three levels, with CIN 1 cells having the lowest risk of becoming cancerous, CIN 2, moderate risk and CIN 3 cells the highest risk.
The study found that vaccinated women born in 1995 and 1996 had undergone an 89% reduction in CIN 3 cells compared to women born in 1988 who had never received the vaccine. The researchers also found an 88% reduction in CIN 2 cells and 79% CIN 1 cells, reported The Independent.
Public Health Minister Joe FitzPatrick told BBC News that the results of this study represented "the important and ongoing benefits of our immunization program," and that the NHS will offer the vaccine to school-aged boys. from next year.
At the launch of the NHS vaccination program, scientists originally thought that the vaccine would protect only two strains of HPV, those responsible for 80% of precancerous diseases, reported BBC News.
Research now suggests that HPV vaccination protects against three additional strains of the virus, eliminating 90% of pre-invasive cervical diseases in Scotland.
CLICK HERE FOR THE FOX NEWS APP
Senior researcher at Glasgow Caledonian University, Kevin Pollock, co-author of the study with Tim Palmer, told The Independent that the study had exceeded expectations.
"It is associated with the virtual elimination of low and high grade cervical disease in young Scottish women eight years after the start of the immunization program," Pollock said. "The numbers are impressive and show a reduction of up to 90% in abnormalities of cervical disease – precancerous cells."
HPV is easily spread through sexual contact, and many women infected with the virus will heal from infection without treatment or symptoms, according to the NHS. However, 99.7% of cervical cancer cases are caused by infection with high-risk HPV strains.
[ad_2]
Source link